Oral, Diabetes Pharm Flashcards

1
Q

Metformin

A

Biguanides

MOA: activates AMPK, increases insulin sensitivity
-decreases cholesterol, TG, and FA synthesis
-increases glucose uptake in skm

AE: DAAMN B
-GI (dia/nausea/abd. dis./metallic taste/low B12)
-Lactic acidosis (rare)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Biguanides (Metformin) Important Considerations

A
  1. First line choice (w. lifestyle changes)
  2. To minimize GI AEs, take with food, start with low dose, and titrate slowly
  3. Contraindicated in patients with predisposing factors to lactic acidosis: (bad kid/LD/alc/HF/inf)
  4. Temp. discontinue metformin in pts at risk of developing lactic acidosis (dehydration/sepsis/IV iodinated contrast)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Pioglitazone, Rosiglitazone

A

Thiazolidinediones (TZDs),“Glitazones”

MOA: PPARy agonist (nuclear rec.) - gene transcription
-increase AMPK/sensitivity/gluc uptake
-decrease glucose production

AE: HII WE
-Hepatotoxicity
-Na/water retention = edema
-Weight gain
-Increase bone fractures
-Increase bladder cancer risk (PIO)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Glitazones: Important Considerations

A
  1. Relatively slow effects
  2. Baseline LFTs/Check LFTs
  3. Monitor for signs of HF (*higher risk if with insulin)
  4. Contraindications:
    -HF
    -Bladder cancer (past/present)
    -Risk of fractures
    -Active liver disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Glimepiride, Glipizide, Glyburide
and Nateglinide, Repaglinide

A

Sulfonylureas and NON-sulf

MOA: bind to sulf rece subunit, increase Ca ch, increase insulin secretion

AE:
-Hypoglycemia (palp/tremor/sweat/anx/hunger/cns)
-Weight gain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

SUs and Non-SUs Considerations

A
  1. Risk factors for hypoglycemia
    -after exercise, missed meal, high dose, alcohol, impaired renal/liver
  2. Will not work in T1 DM pts (no beta cells)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Exenatide, Lixisenatide, Liraglutide, Dulaglutide, Semaglutide

A

glutes = GG

MOA: activates GLP1 receptors

AE:
-GI (nausea/vomit/diarrhea)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Glutides: Important Considerations

A

SO MEN P

  1. Administer SC
  2. Off label use in T1 DM
  3. CI in pts with thyroid cancer or multiple endocrine neoplasia (MEN)
  4. Caution if pancreatitis hx
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Sitagliptin, Linagliptin, Saxagliptin, Alogliptin

A

MOA: inhibits DPP4, increases GLP1 effects

AE: JARR (clip a jar)
-Increase risk of respiratory infection
-Rash
-Angioedema
-Joint pain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Gliptin Important Considerations

A
  1. Use with caution in patients with history of or risk factors for HF = increase hospitalization for HF
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Canagliflozin, Dapagliflozin, Empagliflozin

A

MOA: inhibits SGLT2 in PT

AE: HA LEG off a cliff (gliff)
-Genitourinary infections
-Hypotension
-AKI
-Euglycemic DKA
-Increase risk of lower limb amputations (Cana)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Gliflozins Important Considerations

A

FRON
1. Off label for T1 DM
2. Pt ed about infections (gen)
3. Drink plenty of fluids
4. Risk factors for AKI (caution nsaids/acei/arb)
5. CI: severe renal impair
6. Renal monitoring
7. Risk factors for euglycemic DKA
8. Caution in pts with neuropathy, PAD, foot deformities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

A1c lowering

A

*High (>1.5%): metformin, SUs/non-SUs, GLP-1 agonists

*Medium (1-1.5%): TZDs

*Low (< 1%): DPP-4 inhibitors, SGLT2 inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Weight Loss

A

GLP-1 agonists, SGLT2 inhibitors, metformin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Weight Neutral

A

DPP-4 inhibitors, metformin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Weight Gain

A

TZDs (glitazones), SUs, non-SUs

17
Q

Decrease CV risk

A

GLP-1 agonists, SGLT2 inhibitors

18
Q

Cancer Concerns

A

*Bladder cancer: pioglitazone

*Medullary thyroid cancer: GLP-1 agonists

19
Q

High Hypoglycemia Risk

A

SUs/non-SUs

20
Q

Metabolic Acidosis Risk

A

*Lactic acidosis: metformin

*“Euglycemic” DKA: SGLT2 inhibitors (glifs)

21
Q

Renal Considerations

A

-Metformin

-SGLT2 inhibitors (glifs)

-SUs/non-SUs